ENVB · Enveric Biosciences, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $346.0K | - | $402.4K | $1.26M | $746.4K | - | $762.7K | $515.5K | $458.2K | - |
| SG&A | $1.25M | - | $1.43M | $1.22M | $1.36M | - | $1.24M | $1.30M | $1.93M | - |
| Total Operating Expenses | $1.63M | - | $1.87M | $2.52M | $2.19M | - | $2.08M | $1.90M | $2.48M | - |
| D&A | $37.2K | - | $40.4K | $40.0K | $81.0K | - | $84.8K | $84.8K | $85.4K | - |
| Operating Income | ($1.63M) | - | ($1.87M) | ($2.52M) | ($2.19M) | - | ($2.08M) | ($1.90M) | ($2.48M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | $1.7K | - |
| Net Income | ($1.63M) | - | ($1.87M) | ($2.52M) | ($2.18M) | - | ($2.08M) | ($1.88M) | ($2.46M) | - |
| EPS - Basic | ($1.08) | - | ($10.81) | ($11.64) | ($14.64) | - | ($648.00) | ($675.00) | ($1647.00) | - |
| EPS - Diluted | ($1.08) | - | ($10.81) | ($11.64) | ($14.64) | - | ($648.00) | ($675.00) | ($1647.00) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.91M | $4.68M | $3.76M | $2.85M | $4.29M | $2.24M | $3.11M | $3.50M | $6.36M | $2.29M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $280.3K | $581.0K | $683.7K | $1.04M | $669.2K | $521.7K | $576.3K | $459.9K | $1.85M | $1.22M |
| Current Assets | $5.38M | $4.94M | $4.17M | $3.31M | $4.83M | $2.73M | $4.34M | $5.52M | $8.23M | $3.58M |
| Total Assets | $5.52M | $5.10M | $4.36M | $3.55M | $5.10M | $3.08M | $4.79M | $6.05M | $8.85M | $4.30M |
| Current Liabilities | $460.7K | $918.4K | $905.9K | $1.36M | $1.18M | $1.49M | $839.2K | $645.3K | $2.37M | $2.34M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - |
| Stockholders' Equity | $5.06M | $4.18M | $3.46M | $2.18M | $3.92M | $1.59M | $3.95M | $5.41M | $6.48M | $1.96M |
| Retained Earnings | ($116.48M) | ($114.85M) | ($112.65M) | ($110.78M) | ($108.26M) | ($106.07M) | ($102.92M) | ($100.84M) | ($98.96M) | ($96.50M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($2.26M) | - | - | - | ($2.39M) | - | - | - | ($2.60M) | - |
| Investing Cash Flow | - | - | - | - | - | - | - | - | - | - |
| Financing Cash Flow | $2.50M | - | - | - | $4.45M | - | - | - | $6.66M | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -29.6% | - | -43.0% | -71.0% | -42.8% | - | -43.5% | -31.1% | -27.8% | - |
| Return on equity | -32.3% | - | -54.2% | -115.3% | -55.8% | - | -52.7% | -34.8% | -37.9% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 11.67 | 5.38 | 4.60 | 2.43 | 4.08 | 1.84 | 5.17 | 8.55 | 3.48 | 1.53 |
| Quick ratio | 11.67 | 5.38 | 4.60 | 2.43 | 4.08 | 1.84 | 5.17 | 8.55 | 3.48 | 1.53 |
| Cash ratio | 10.66 | 5.09 | 4.15 | 2.09 | 3.63 | 1.50 | 3.71 | 5.43 | 2.68 | 0.98 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.09 | 1.22 | 1.26 | 1.62 | 1.30 | 1.94 | 1.21 | 1.12 | 1.37 | 2.20 |
| Liabilities / Assets | - | - | - | - | - | - | - | - | - | - |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 0.6x | - | 0.7x | 17.3x | 7.7x | - | 2818.9x | 2372.2x | 1666.8x | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 25.3% | - | 10.0% | -32.7% | 11.7% | - | 39.6% | 67.0% | 49.0% | - |
| Net income growth (YoY) | 25.2% | - | 10.1% | -34.0% | 11.1% | - | 26.2% | 70.4% | 47.5% | - |
| EPS growth (YoY) | 92.6% | - | 98.3% | 98.3% | 99.1% | - | -44283.6% | -24625.3% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 29.2% | 162.3% | -12.5% | -59.6% | -39.6% | -18.6% | 62.2% | 10.9% | -37.7% | -86.7% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Enveric Biosciences against the 5 most active filers in the same SIC group.